Navigation Links
Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the 29th Annual J.P. Morgan Healthcare Conference to be held on January 9-13, 2011 in San Francisco. Gregory Frost, Ph.D., president and CEO, will present an overview of Halozyme's business strategy and its product development pipeline on Wednesday, January 12, 2011 at 3:30 p.m. PST (6:30 p.m. EST). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter Bi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") ... company specializing in personalized medicine, to participate in ... to evaluate the safety and efficacy of HLD-200, ... disorder (ADHD). This is Restore,s second clinical trial ... partnered with Ironshore in 2014 and continues to ...
(Date:8/3/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2015.  Financial and operating highlights for the quarter ... 2015 revenue by 6 percent to $58.9 million, over ... quarter 2015 assay revenue by 22 percent to $24.2 ... , Increased Q2 2015 royalty revenue by 17 ...
(Date:8/3/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today financial results ... million and net loss was $5.5 million for the three ... of $4.6 million and net loss of $5.5 million for ... we had cash and investments of $37.8 million, compared to ... At June 30, 2015, we had $19.8 million in long ...
Breaking Medicine Technology:Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... 31st European Cystic Fibrosis Conference -, SOUTH ... /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) today announced promising ... fibrosis (CF). Results from an Israeli Phase 2a,extension ... in adult,patients with nonsense-mutation-mediated CF demonstrated statistically,significant improvements ...
... Data from Positive Phase 2a Trial, WALTHAM, ... ) today announced that based on feedback from ... initiate a Phase 2b clinical,trial of RG2417, an ... later this year. This will be a multi-center, ...
Cached Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5
(Date:8/4/2015)... , ... August 04, 2015 , ... ... patients whose cancer has come back: Retreatment may be a viable option. Surviving ... read it now. , According to surgeons at the University of New ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin ... unique artistic expressions from a diverse group of exceptionally talented female artists. ... & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated by ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... specializing in healthcare finance, announced the closing of a $118 million FHA-insured loan ... health system located in Smithfield and Clayton, North Carolina. JHSC is a ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a ... Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were published on June ... According to the results of the trial, the implant, more commonly known as the ...
(Date:8/4/2015)... ... , ... Centurion Service Group, the world's largest medical equipment auction house, will ... The live auction will take place on Thursday, August 6 beginning at ... 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2
... risks from prescription drugs, survey suggests , THURSDAY, July ... link between pop star Michael Jackson,s death and his ... public,s concern about prescription medication overdose risks, suggests a ... 200 respondents who work in home, ambulatory and chronic ...
... healthcare reform a high priority on the national agenda, Shan ... leading provider of Health Management Solutions, believes the market is ... down costs while also improving healthcare quality for all Americans. ... ) , , "Despite a down economy, health ...
... CHICAGO, July 9 In these amazing times, with real ... are endless for registered dietitians in keeping the public we ... Dietetic Association,s key tenets is that every American has a ... and that this right includes access to healthy food from ...
... Carriage Services, Inc. (NYSE: CSV ) today announced plans ... after the market closes. In conjunction with the release, Carriage ... over the Internet, for Friday, July 31, 2009 at 10:30 a.m. ... Carriage Services Second Quarter 2009 Earnings Conference Call, ...
... SANTA MONICA, Calif. and LAS VEGAS, July 9 Cord ... largest umbilical cord blood stem cell preservation companies ( ... saving potential of stem cells to families nationwide and internationally, ... square foot building in Las Vegas, Nevada, for a state-of-the-art ...
... ... and Germicidal UV Modules from healthcare facilities as they activate their emergency pandemic ... ... strong demand for their HEPA-CARE® Air Filtration Systems and Germicidal UV Modules from ...
Cached Medicine News:Health News:Questions to Pharmacists Rise After Michael Jackson's Death 2Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 2Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 3Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 4Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 5Health News:Statement by Registered Dietitian and American Dietetic Association President Jessie M. Pavlinac on Health Reform and Conservation of Natural Resources 2Health News:Carriage Services Announces Second Quarter Earnings Release and Conference Call Schedule 2Health News:Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 2Health News:Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 3Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 3
... perfused manometric catheters for esophageal, ... tests. All Medtronic Water Perfused ... medical grade PVC tubing. For ... you will find a number ...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
... We have water perfused manometric ... vector volume diagnostic tests. All ... made using clear, medical grade ... in the esophagus you will ...
Replacement Stopper for LATITUDE® Air-Charged Catheter...
Medicine Products: